• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

人胎盘外植体对新冠病毒mRNA疫苗暴露的最小mRNA摄取和炎症反应。

Minimal mRNA uptake and inflammatory response to COVID-19 mRNA vaccine exposure in human placental explants.

作者信息

Gonzalez Veronica J, Li Lin, Buarpung Sirirak, Prahl Mary, Robinson Joshua F, Gaw Stephanie L

机构信息

Division of Maternal-Fetal Medicine, Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California, San Francisco, San Francisco, CA 94158, USA.

Center for Reproductive Sciences, Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California, San Francisco, San Francisco, CA 94143, USA.

出版信息

iScience. 2023 Aug 7;26(9):107549. doi: 10.1016/j.isci.2023.107549. eCollection 2023 Sep 15.

DOI:10.1016/j.isci.2023.107549
PMID:37664582
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10470080/
Abstract

Despite universal recommendations for COVID-19 mRNA vaccination in pregnancy, uptake has been lower than desired. There have been limited studies of the direct impact of COVID-19 mRNA vaccine exposure in human placental tissue. Using a primary human placental explants model, we investigated the uptake of two common mRNA vaccines (BNT162b2 Pfizer-BioNTech or mRNA-1273 Moderna), and whether exposure altered villous cytokine responses. Explants derived from second or third trimester chorionic villi were incubated with vaccines at supraphysiologic concentrations and analyzed at two time points. We observed minimal uptake of mRNA vaccines in placental explants by hybridization and quantitative RT-PCR. No specific or global cytokine response was elicited by either of the mRNA vaccines in multiplexed immunoassays. Our results suggest that the human placenta does not readily absorb the COVID-19 mRNA vaccines nor generate a significant inflammatory response after exposure.

摘要

尽管普遍建议在孕期接种新冠病毒mRNA疫苗,但接种率一直低于预期。关于新冠病毒mRNA疫苗暴露对人胎盘组织的直接影响的研究有限。我们使用原代人胎盘外植体模型,研究了两种常见mRNA疫苗(BNT162b2辉瑞-生物科技或mRNA-1273莫德纳)的摄取情况,以及暴露是否会改变绒毛细胞因子反应。将来自妊娠中期或晚期绒毛膜绒毛的外植体与超生理浓度的疫苗一起孵育,并在两个时间点进行分析。通过杂交和定量逆转录聚合酶链反应,我们观察到胎盘外植体对mRNA疫苗的摄取极少。在多重免疫测定中,两种mRNA疫苗均未引发特异性或全身性细胞因子反应。我们的结果表明,人胎盘不易吸收新冠病毒mRNA疫苗,暴露后也不会产生显著的炎症反应。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4f7f/10470080/6b9981098b2c/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4f7f/10470080/be9bd60e1b6b/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4f7f/10470080/c1ca1728e60d/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4f7f/10470080/e50e0befd271/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4f7f/10470080/6b9981098b2c/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4f7f/10470080/be9bd60e1b6b/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4f7f/10470080/c1ca1728e60d/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4f7f/10470080/e50e0befd271/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4f7f/10470080/6b9981098b2c/gr3.jpg

相似文献

1
Minimal mRNA uptake and inflammatory response to COVID-19 mRNA vaccine exposure in human placental explants.人胎盘外植体对新冠病毒mRNA疫苗暴露的最小mRNA摄取和炎症反应。
iScience. 2023 Aug 7;26(9):107549. doi: 10.1016/j.isci.2023.107549. eCollection 2023 Sep 15.
2
Minimal mRNA uptake and inflammatory response to COVID-19 mRNA vaccine exposure in human placental explants.人胎盘外植体对新冠病毒mRNA疫苗暴露的mRNA摄取和炎症反应极小。
medRxiv. 2023 Feb 2:2023.02.01.23285349. doi: 10.1101/2023.02.01.23285349.
3
[F]FDG uptake of axillary lymph nodes after COVID-19 vaccination in oncological PET/CT: frequency, intensity, and potential clinical impact.COVID-19 疫苗接种后肿瘤 PET/CT 腋窝淋巴结的 FDG 摄取:频率、强度和潜在的临床影响。
Eur Radiol. 2022 Jan;32(1):508-516. doi: 10.1007/s00330-021-08122-2. Epub 2021 Jun 22.
4
Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions - United States, March-August 2021.2021年3月至8月美国Moderna、辉瑞-生物科技公司和杨森(强生)疫苗在预防无免疫功能低下状况成年人新冠病毒肺炎住院方面的比较效果
MMWR Morb Mortal Wkly Rep. 2021 Sep 24;70(38):1337-1343. doi: 10.15585/mmwr.mm7038e1.
5
Immunogenicity and safety of a booster dose of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2 mRNA COVID-19 vaccine: a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial.一种自我扩增 RNA COVID-19 疫苗(ARCT-154)与 BNT162b2 mRNA COVID-19 疫苗加强针的免疫原性和安全性:一项双盲、多中心、随机、对照、3 期、非劣效性试验。
Lancet Infect Dis. 2024 Apr;24(4):351-360. doi: 10.1016/S1473-3099(23)00650-3. Epub 2023 Dec 20.
6
COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.COVID-19 疫苗:辉瑞/生物科技和 Moderna 疫苗的生物学、药理学特征和不良反应比较。
Eur Rev Med Pharmacol Sci. 2021 Feb;25(3):1663-1669. doi: 10.26355/eurrev_202102_24877.
7
Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study.真实世界中衰弱老年人接受延长间隔和异源 COVID-19 mRNA 疫苗接种后的血清学反应(UNCoVER):一项前瞻性观察队列研究的中期报告。
Lancet Healthy Longev. 2022 Mar;3(3):e166-e175. doi: 10.1016/S2666-7568(22)00012-5. Epub 2022 Feb 23.
8
Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices - United States, July 2021.在报告 Janssen(强生)和 mRNA COVID-19 疫苗(辉瑞-生物科技和莫德纳)成年受种者发生不良事件后使用 COVID-19 疫苗:免疫实践咨询委员会的更新-美国,2021 年 7 月。
MMWR Morb Mortal Wkly Rep. 2021 Aug 13;70(32):1094-1099. doi: 10.15585/mmwr.mm7032e4.
9
Incidence, risk factors, natural history, and hypothesised mechanisms of myocarditis and pericarditis following covid-19 vaccination: living evidence syntheses and review.新型冠状病毒肺炎(COVID-19)疫苗接种后心肌炎和心包炎的发生率、危险因素、自然史和假设发病机制:基于实时证据的综合分析和综述。
BMJ. 2022 Jul 13;378:e069445. doi: 10.1136/bmj-2021-069445.
10
Differences in IgG Antibody Responses following BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines.BNT162b2 和 mRNA-1273 两种 SARS-CoV-2 疫苗接种后的 IgG 抗体反应差异。
Microbiol Spectr. 2021 Dec 22;9(3):e0116221. doi: 10.1128/Spectrum.01162-21. Epub 2021 Nov 10.

引用本文的文献

1
An ex vivo human placental explant model for controlled exposure studies.用于对照暴露研究的体外人胎盘外植体模型。
STAR Protoc. 2025 Sep 19;6(3):104055. doi: 10.1016/j.xpro.2025.104055. Epub 2025 Aug 29.
2
The association between coronavirus disease 2019 vaccination during pregnancy and neonatal health outcomes.孕期接种2019冠状病毒病疫苗与新生儿健康结局之间的关联。
Pediatr Investig. 2024 Nov 7;9(1):41-51. doi: 10.1002/ped4.12456. eCollection 2025 Mar.
3
BNT162b2 COVID-19 vaccination elicits the expansion of CD16CD8 T cells endowed with natural killer cell features.

本文引用的文献

1
SARS-CoV-2 spike mRNA vaccine sequences circulate in blood up to 28 days after COVID-19 vaccination.SARS-CoV-2 刺突 mRNA 疫苗序列在 COVID-19 接种后长达 28 天在血液中循环。
APMIS. 2023 Mar;131(3):128-132. doi: 10.1111/apm.13294. Epub 2023 Jan 29.
2
Evaluation of transplacental transfer of mRNA vaccine products and functional antibodies during pregnancy and infancy.评估 mRNA 疫苗产品在妊娠和婴儿期的胎盘转移及其功能性抗体。
Nat Commun. 2022 Jul 30;13(1):4422. doi: 10.1038/s41467-022-32188-1.
3
Vaccine mRNA Can Be Detected in Blood at 15 Days Post-Vaccination.
BNT162b2新冠疫苗接种引发具有自然杀伤细胞特征的CD16⁺CD8⁺T细胞扩增。
J Allergy Clin Immunol. 2025 Jun;155(6):1981-1992. doi: 10.1016/j.jaci.2025.01.024. Epub 2025 Jan 31.
4
Review on the bioanalysis of non-virus-based gene therapeutics.基于非病毒的基因治疗药物的生物分析综述。
Bioanalysis. 2024 Dec-Dec;16(23-24):1279-1294. doi: 10.1080/17576180.2024.2437418. Epub 2024 Dec 14.
5
Safety, effectiveness and immunogenicity of heterologous mRNA-1273 boost after prime with Ad26.COV2.S among healthcare workers in South Africa: The single-arm, open-label, phase 3 SHERPA study.南非医护人员中以Ad26.COV2.S为初免后异源mRNA-1273加强免疫的安全性、有效性和免疫原性:单臂、开放标签的3期SHERPA研究
PLOS Glob Public Health. 2024 Dec 5;4(12):e0003260. doi: 10.1371/journal.pgph.0003260. eCollection 2024.
6
Neonatal Outcomes After COVID-19 Vaccination in Pregnancy.孕期接种新冠病毒疫苗后的新生儿结局
JAMA. 2024 Feb 6;331(5):396-407. doi: 10.1001/jama.2023.26945.
7
Biodistribution of RNA Vaccines and of Their Products: Evidence from Human and Animal Studies.RNA疫苗及其产物的生物分布:来自人类和动物研究的证据。
Biomedicines. 2023 Dec 26;12(1):59. doi: 10.3390/biomedicines12010059.
8
Neoantigen vaccine nanoformulations based on Chemically synthesized minimal mRNA (CmRNA): small molecules, big impact.基于化学合成最小化信使核糖核酸(CmRNA)的新抗原疫苗纳米制剂:小分子,大作用。
NPJ Vaccines. 2024 Jan 18;9(1):14. doi: 10.1038/s41541-024-00807-1.
接种疫苗后15天可在血液中检测到疫苗mRNA。
Biomedicines. 2022 Jun 28;10(7):1538. doi: 10.3390/biomedicines10071538.
4
Placental pathology in women vaccinated and unvaccinated against SARS-CoV-2.接种和未接种SARS-CoV-2疫苗的女性的胎盘病理学
Am J Obstet Gynecol. 2022 Nov;227(5):782-784. doi: 10.1016/j.ajog.2022.06.039. Epub 2022 Jun 28.
5
Maternal Vaccination and Risk of Hospitalization for Covid-19 among Infants.母亲接种疫苗与婴儿因 Covid-19 住院的风险。
N Engl J Med. 2022 Jul 14;387(2):109-119. doi: 10.1056/NEJMoa2204399. Epub 2022 Jun 22.
6
Neutralizing antibody activity against SARS-CoV-2 variants in gestational age-matched mother-infant dyads after infection or vaccination.感染或接种疫苗后,与妊娠年龄匹配的母婴对 SARS-CoV-2 变体的中和抗体活性。
JCI Insight. 2022 Jun 22;7(12):e157354. doi: 10.1172/jci.insight.157354.
7
Effectiveness of Maternal Vaccination with mRNA COVID-19 Vaccine During Pregnancy Against COVID-19-Associated Hospitalization in Infants Aged <6 Months - 17 States, July 2021-January 2022.mRNA 新冠疫苗在妊娠期间对 6 月龄以下婴儿的 COVID-19 相关住院的有效性-17 个州,2021 年 7 月-2022 年 1 月。
MMWR Morb Mortal Wkly Rep. 2022 Feb 18;71(7):264-270. doi: 10.15585/mmwr.mm7107e3.
8
Maternal-fetal immune responses in pregnant women infected with SARS-CoV-2.孕妇感染 SARS-CoV-2 时的母婴免疫反应。
Nat Commun. 2022 Jan 18;13(1):320. doi: 10.1038/s41467-021-27745-z.
9
Maternal and Neonatal SARS-CoV-2 Immunoglobulin G Antibody Levels at Delivery After Receipt of the BNT162b2 Messenger RNA COVID-19 Vaccine During the Second Trimester of Pregnancy.孕妇在妊娠中期接种 BNT162b2 信使 RNA COVID-19 疫苗后,分娩时母胎 SARS-CoV-2 免疫球蛋白 G 抗体水平。
JAMA Pediatr. 2022 Mar 1;176(3):290-295. doi: 10.1001/jamapediatrics.2021.5683.
10
Efficient maternal to neonatal transfer of antibodies against SARS-CoV-2 and BNT162b2 mRNA COVID-19 vaccine.针对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)和BNT162b2 mRNA新冠疫苗的抗体从母体到新生儿的高效转移。
J Clin Invest. 2021 Oct 1;131(19). doi: 10.1172/JCI154834.